Health

Rep. Dean supports universal, affordable high-quality healthcare.

Defending the Affordable Care Act and Expanding Care

The Affordable Care Act (ACA) and Medicaid expansion have meant health coverage for tens of millions of Americans – including more than a million Pennsylvanians.

Since her first day in Congress, Rep. Dean has fought to defend the ACA against a lawsuit and repeated attacks from the administration. She also voted to pass H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act, a bipartisan package of seven bills focused on eliminating barriers to health care. H.R. 987 boosts patients’ access to coverage by defending protections for pre-existing conditions, supporting state-based marketplaces, and funding outreach and enrollment efforts. The bill also aims to lower the cost of prescription drugs by bringing generic medications to market more quickly.

The Opioid Crisis

Rep. Dean is working hard to address the opioid crisis and America’s broader drug overdose epidemic, which now claims 70,000 lives each year. She is a member of the bipartisan Freshman Working Group on Addiction, and she speaks regularly about the importance of destigmatization and increased funding for treatment.

Suicide and Gun Violence Prevention

Rep. Dean is keenly focused on America’s suicide problem. In her first seven months in office, she partnered with Republican Rep. Guy Reschenthaler (PA-14) to pass the STOIC Act, which allocates funds for suicide prevention efforts in police departments across the country. The bill was signed into law on July 25, 2019.

Gun violence also exacts a heavy toll on Americans’ health and wellbeing. Firearms kill 40,000 Americans and wound 134,000 more each year – to say nothing of the trauma these incidents cause for our communities. Rep. Dean seeks to address this scourge by passing common-sense gun safety legislation, including universal background checks and a red flag law. In fact, the House has passed two bills – H.R. 8 and H.R. 1112 – that would close loopholes in the background check system and make it more difficult for prohibited purchasers to obtain firearms.

Women’s Reproductive Health

Rep. Dean unequivocally supports the right of women to make intimate medical decisions in consultation with their doctors. She has spoken out against the Trump administration’s efforts to force Planned Parenthood to withhold medical information, and she is a co-sponsor of the Women’s Health Protection Act of 2019, which protects a woman’s ability to determine whether and when to bear a child – and defends the rights of healthcare providers to provide reproductive health services.

Rep. Dean is also a co-sponsor of the Reproductive Rights are Human Rights Act of 2019, which directs the State Department to record information on reproductive rights in its human rights report.

PFAS

Perfluoroalkyl or polyfluoroalkyl (PFAS) chemicals are linked to a range of health consequences, including certain types of cancers and impaired immune system performance. The chemicals have long been used in a range of consumer products, and the military continues to use aqueous film-forming foam (AFFF) in firefighting training exercises. Across the country, these chemicals flow from military bases into community water supplies, exposing tens of millions of people to health risks.

In Pennsylvania’s Fourth Congressional District – Montgomery and Berks Counties – the epicenter of the PFAS problem is Naval Air Station Joint Reserve Base Willow Grove, where unchecked contamination continues to harm surrounding municipalities. In May, Rep. Dean toured the base with members of the Congressional PFAS Task Force and witnessed this ongoing contamination.

In Congress, Rep. Dean is leading the fight to protect communities from PFAS. She is a founding member of the bipartisan PFAS Task Force, and she has introduced H.R. 2600, the Toxic PFAS Control Act, to list and regulate PFAS chemicals under the Toxic Substances Control Act (TSCA). This bill would phase out PFAS by banning the manufacturing and processing of these chemicals, while also requiring the Environmental Protection Agency (EPA) to regulate their disposal.

In July, the House of Representatives also passed the National Defense Authorization Act (NDAA), including two amendments sponsored by Rep. Dean that address PFAS water contamination.

Rep. Dean’s first amendment provides an additional $5 million to the Centers for Disease Control and Prevention’s (CDC) Agency for Toxic Substances and Disease Registry (ATSDR) to conduct the nation’s first PFAS health study, authorizing a total of $15 million for this critical research.  

Rep. Dean also led a letter in support of the Pennsylvania Department of Health’s (PADOH) grant application, and the CDC selected Montgomery County, Pennsylvania as one of just seven sites for the nationwide study. Montgomery County will receive $1 million in grant funding.

Rep. Dean’s second amendment to the NDAA phases out the Department of Defense’s (DoD) use of AFFF by 2025—reducing PFAS contamination and protecting our communities.

The amendment also limits DoD’s ability to use waivers – from 6 years to 1 year. Currently, DoD can use waivers that allow the use of AFFF up to 2035 – almost a decade longer than Rep. Dean’s phase-out provision would allow.  

Along with Rep. Andy Kim (NJ-03) and Rep. Xochitl Torres Small, (NM-02), Rep. Dean has also introduced H.R. 4295, the Protect Our Military Children Act, a bill that will require the Department of Defense to carry out blood testing services for children living at military facilities and track levels of PFAS chemicals. 

In addition, Rep. Dean is working with other Members of Congress to pressure the Environmental Protection Agency (EPA) to establish an enforceable Maximum Contaminant Level for PFAS – an essential element in any effort to combat our water contamination challenge.

 

 

More on Health

November 18, 2020 Press Release

WASHINGTON – Today, the House voted unanimously passed H.R. 4712, the Fairness in Orphan Drug Exclusivity Act.

October 30, 2020 Press Release

WASHINGTON Today, Rep. Dean introduced the Education for New Dispositions on Stigma (END Stigma) Act. According to the Recovery Research Institute, “Illicit drug use disorder is the most stigmatized health condition in the world.” The END Stigma Act establishes a university grant program to educate students on substance use disorder treatment options. 

October 21, 2020 Press Release

Blue Bell, PA – Last night, Rep. Madeleine Dean (PA-04) hosted her very first drive-in town hall at the Montgomery County Community College’s Blue Bell Campus. The drive-in town hall was an opportunity for constituents to safely connect with Congresswoman Dean. Topics included the COVID-19 relief and vaccine, the opioid crisis, climate change, the economy, and more. 

September 30, 2020 Press Release

WASHINGTON -- Today, Reps. Dean and Lawrence introduced H.Res.1160 to recognize September 2020 as “Pain Awareness Month” and the disproportionate impact of migraine disease and headache disorders on women. 

September 22, 2020 Press Release

WASHINGTON Reps. Dean, and Blunt Rochester introduced the Community Health Center Mental Health Screening Act. This legislation works to increase federal investment in mental health screenings and services in community health centers.

August 5, 2020 Press Release

WASHINGTON Last week, the House passed a package of the fiscal year 2021 appropriations bills, including Rep. Dean’s proposed funding for people with disabilities, pregnant and postpartum women dealing with substance abuse, the national PFAS health study, student loan borrowers, and gun violence prevention. 

 

August 3, 2020 Press Release

WASHINGTON – Rep. Dean introduced the bipartisan PFAS Free Foam Research and Development Act, in order to find an alternative to PFAS contaminated firefighting foam. 

"Tackling our local – and national – water contamination problem is one of my highest priorities,” Rep. Dean said. “Finding an alternative to PFAS contaminated firefighting foam is vital –   no one should be exposed to these harmful forever chemicals."

July 24, 2020 Press Release

WASHINGTON Rep. Dean introduced the MORE Savings Act in the House, mirroring the Senate bill introduced by Sen. Bob Casey. Every day, more than 115 Americans overdose and die from opioid misuse. Addressing the nation’s opioid crisis requires a multi-faceted strategy that includes prevention, treatment, law enforcement and recovery support.

 

July 15, 2020 Press Release

WASHINGTON – Today H.R. 4712, the Fairness in Orphan Drug Exclusivity Act, unanimously passed out of the House Energy and Commerce Committee. The legislation will now go to the House Floor for consideration.

The bipartisan bill introduced by Rep. Madeleine Dean (PA-04), Marc Veasey (TX-33), Earl L. “Buddy” Carter (GA-01), and David McKinley (WV-01), closes a loophole that blocks pharmaceutical competition and prevents innovative treatments for opioid use disorder from coming to market.

May 21, 2020 Press Release

WASHINGTON, D.C. – Yesterday, House Health Subcommittee Chairwoman Anna G. Eshoo (CA-18), Consumer Protection and Commerce Subcommittee Chair Jan Schakowsky (IL-09) and Representatives Madeleine Dean (PA-04), Donna Shalala (FL-27), and Seth Moulton (MA-06) introduced legislation to provide $20 billion to help states, nursing homes, and intermediate care facilities contain the spread of COVID-19 to protect residents and staff.